StockData
LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Longeveron Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.39+0.00 (0.00%)

Close on Oct 19, 2026

Market cap
$43.61M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 3, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 12, 2026After market close–––
Q1 FY2026
Ended Mar 31, 2026
May 13, 2026After market close$398.00K$-0.19–
Q3 FY2025
Ended Sep 30, 2025
Nov 4, 2025After market close–––
Q2 FY2025
Ended Jun 30, 2025
Aug 13, 2025After market close–––
Q1 FY2025
Ended Mar 31, 2025
May 8, 2025After market close$400.00K$-0.34–
Q4 FY2024
Ended Dec 31, 2024
Feb 28, 2025After market close–––
Q3 FY2024
Ended Sep 30, 2024
Nov 12, 2024After market close$773.00K$-0.34–
Q2 FY2024
Ended Jun 30, 2024
Aug 14, 2024After market close–––
Q1 FY2023
Ended Mar 31, 2023
May 12, 2023Before market open–––
Q4 FY2022
Ended Dec 31, 2022
Mar 10, 2023During market hours–––
Q2 FY2022
Ended Jun 30, 2022
Aug 12, 2022Before market open–––

Press releases

Announcements Longeveron filed with the SEC